Analysis of the Effects of EPA and DHA on Cardiomyocyte hypertrophy

Katayama, Ayumi; Funamoto, Masafumi; Shimizu, Kana; Mai, Gempei; Sunagawa, Yoichi; Wada, Hiromichi; Hasegawa, Koji; Morimoto, Tatsuya

doi:10.15420/ecr.2018.13.2.po2

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found decreased concentrations of the PUFAs eicosapentaenoate (EPA), arachidonate, and docosahexaenoate (DHA) in participants carrying pathogenic HCM genetic variants. In vitro studies have shown that EPA and DHA repress hypertrophic responses in cardiomyocytes by the direct inhibition of histone acetyltransferase activity, and that EPA attenuates endothelin 1 (ET-1)-induced cardiomyocyte hypertrophy [ 35 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

Metabolite Signature in the Carriers of Pathogenic Genetic Variants for Cardiomyopathy: A Population-Based METSIM Study

et al. 2022

View full text Add to dashboard Cite

Hypertrophic (HCM) and dilated (DCM) cardiomyopathies are among the leading causes of sudden cardiac death. We identified 38 pathogenic or likely pathogenic variant carriers for HCM in three sarcomere genes (MYH7, MYBPC3, TPMI) among 9.928 participants of the METSIM Study having whole exome sequencing data available. Eight of them had a clinical diagnosis of HCM. We also identified 20 pathogenic or likely pathogenic variant carriers for DCM in the TTN gene, and six of them had a clinical diagnosis of DCM. The aim of our study was to investigate the metabolite signature in the carriers of the pathogenic or likely pathogenic genetic variants for HCM and DCM, compared to age- and body-mass-index-matched controls. Our novel findings were that the carriers of pathogenic or likely pathogenic variants for HCM had significantly increased concentrations of bradykinin (des-arg 9), vanillactate, and dimethylglycine and decreased concentrations of polysaturated fatty acids (PUFAs) and lysophosphatidylcholines compared with the controls without HCM. Additionally, our novel findings were that the carriers of pathogenic or likely pathogenic variants for DCM had significantly decreased concentrations of 1,5-anhydrogluticol, histidine betaine, N-acetyltryptophan, and methylsuccinate and increased concentrations of trans-4-hydroxyproline compared to the controls without DCM. Our population-based study shows that the metabolite signature of the genetic variants for HCM and DCM includes several novel metabolic pathways not previously described.

show abstract

Section: Discussionmentioning

confidence: 99%